Scarica l'app Stockscreener
17.83
1.60%
0.30
Precedente Chiudi:
$17.53
Aprire:
$17.9
Volume 24 ore:
706.06K
Relative Volume:
0.65
Capitalizzazione di mercato:
$1.27B
Reddito:
$114.04M
Utile/perdita netta:
$-330.15M
Rapporto P/E:
-3.7696
EPS:
-4.73
Flusso di cassa netto:
$-274.85M
1 W Prestazione:
+21.24%
1M Prestazione:
+18.73%
6M Prestazione:
+70.92%
1 anno Prestazione:
+139.06%
Intervallo 1D:
$17.29
$18.28
Intervallo di 1 settimana:
$14.53
$18.28
Portata 52W:
$2.21
$18.28
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
17.80 | 1.25B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.21 | 115.75B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.84 | 80.71B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.53 | 52.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
850.07 | 52.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.65 | 37.29B | 447.02M | -1.18B | -906.14M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Raymond James | Strong Buy |
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals stock hits 52-week high at $17.87 - Investing.com
Bull Run: Why Phathom Pharmaceuticals Inc. stock is favored by pension funds2025 Winners & Losers & Weekly Stock Performance Updates - Улправда
Is Phathom Pharmaceuticals Inc. stock cheap at current valuationWeekly Profit Report & Daily Profit Maximizing Tips - DonanımHaber
Will Phathom Pharmaceuticals Inc. stock benefit from AI adoptionBear Alert & Verified Momentum Watchlists - Улправда
Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Update Summary & Expert Curated Trade Setup Alerts - ulpravda.ru
Market Moves: Is Phathom Pharmaceuticals Inc. stock oversold or undervalued2025 Winners & Losers & Consistent Income Trade Ideas - ulpravda.ru
US Market Wrap: Is Phathom Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 1-Year HighWhat's Next? - MarketBeat
Is Phathom Pharmaceuticals Inc. stock oversold or undervaluedJuly 2025 Recap & Detailed Earnings Play Strategies - Улправда
Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
Earnings Recap: Can Phathom Pharmaceuticals Inc stock weather global recessionPortfolio Gains Report & Real-Time Stock Entry Alerts - moha.gov.vn
Phathom Pharmaceuticals Inc Stock Analysis and ForecastEarnings Miss Alerts & Affordable Portfolio Tips - earlytimes.in
Raymond James Financial Begins Coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) - MarketBeat
Frazier Life Sciences Management L.P. Purchases 2,357,210 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Reaches New 12-Month HighWhat's Next? - MarketBeat
683 Capital Management LLC Grows Stock Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals stock hits 52-week high at $16.27 By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals stock hits 52-week high at $16.27 - Investing.com India
Raymond James initiates Phathom Pharmaceuticals stock with Strong Buy rating - Investing.com Canada
Phathom Pharmaceuticals (NASDAQ:PHAT) Upgraded at Barclays - MarketBeat
(PHAT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Barclays Initiates Coverage of Phathom Pharmaceuticals (PHAT) with Equal-Weight Recommendation - Nasdaq
Barclays Initiates Phathom Pharmaceuticals at Equalweight With $16 Price Target - marketscreener.com
Is WPIL Limited Still a Good Stock to Buy After Recent Earnings - earlytimes.in
Responsive Playbooks and the PHAT Inflection - news.stocktradersdaily.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Sets New 1-Year HighWhat's Next? - MarketBeat
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals stock hits 52-week high at 16.08 USD - Investing.com
Is Phathom Pharmaceuticals Inc a good long term investmentIPO Market Watch & Budget Friendly Capital Growth - earlytimes.in
How Phathom Pharmaceuticals Inc. stock benefits from strong dollarJuly 2025 Earnings & Accurate Intraday Trading Signals - moha.gov.vn
Phathom Pharmaceuticals research links GLP-1 use to higher GERD risk - Traders Union
Phathom Pharmaceuticals Inc. (PHAT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth (NASDAQ:PHAT) - Seeking Alpha
What Wall Street predicts for Phathom Pharmaceuticals Inc. stock priceJuly 2025 Macro Moves & Safe Entry Momentum Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a contrarian buyGap Up & Daily Growth Stock Tips - newser.com
Is Phathom Pharmaceuticals Inc. stock a smart buy before Fed meeting2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
What margin trends mean for Phathom Pharmaceuticals Inc. stockJuly 2025 Summary & Daily Stock Momentum Reports - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Market Sentiment & Safe Entry Trade Reports - newser.com
Understanding the Setup: (PHAT) and Scalable Risk - news.stocktradersdaily.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they meanMarket Risk Analysis & Growth Oriented Trade Recommendations - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 20252025 Top Decliners & Proven Capital Preservation Methods - newser.com
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
0.02%
3.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):